Blueprint Med(BPMC.US)

Last Updated 19:00:00 ET
longbridge loading

Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout

Pharmaceutical Technology·
US
GILD
-0.05%
US
SBIO
+1.57%
US
IHE
+0.71%
Pharmaceutical Technology·
US
GILD
-0.05%
US
SBIO
+1.57%
US
IHE
+0.71%

Galapagos Seeks Strategic Tie-Up With Gilead Around Ouro Medicines Deal and T Cell Engager OM336

Tip Ranks·
US
GLPG
0.00%
US
IBB
+0.63%
US
LABU
+1.66%
Tip Ranks·
US
GLPG
0.00%
US
IBB
+0.63%
US
LABU
+1.66%

Rights to antibody drug from China’s Keymed change hands in US acquisition

SCMP·
US
XBI
+0.62%
US
SBIO
+1.57%
US
IBBQ
+0.64%
SCMP·
US
XBI
+0.62%
US
SBIO
+1.57%
US
IBBQ
+0.64%

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases | GILD Stock News

StockTitan·
DE
GIS
0.00%
US
FBT
+0.52%
StockTitan·
DE
GIS
0.00%
US
FBT
+0.52%

Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis

PharmaTimes·
US
PBE
+0.33%
US
IXJ
+0.49%
US
ALDX
-0.19%
PharmaTimes·
US
PBE
+0.33%
US
IXJ
+0.49%
US
ALDX
-0.19%

Four-year data shows long-term benefit and safety of AYVAKIT in Indolent Systemic Mastocytosis. 12 presentations at AAAAI Meeting.

Unusual Whales·
US
IBBQ
+0.64%
US
IBB
+0.63%
US
BBH
+0.63%
Unusual Whales·
US
IBBQ
+0.64%
US
IBB
+0.63%
US
BBH
+0.63%

09:45 ETBlueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis

prnewswire·
US
BIB
+0.08%
US
IXJ
+0.49%
US
PBE
+0.33%
prnewswire·
US
BIB
+0.08%
US
IXJ
+0.49%
US
PBE
+0.33%

BeOne Medicines Earnings Report: Q4 Overview

benzinga_article·
US
IXJ
+0.49%
US
BIB
+0.08%
US
XBI
+0.62%
benzinga_article·
US
IXJ
+0.49%
US
BIB
+0.08%
US
XBI
+0.62%
© 2026 Longbridge｜Disclaimer